• Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

    Not recruiting

    3 1 1
    Italy Spain
  • Study of Monalizumab and Volrustomig for Patients with MSI and/or dMMR Metastatic Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • A study of low-dose interleukin-2 (aldesleukin) treatment in patients with early Alzheimer’s Disease

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study on the Emotional Effects of Morphine, Oxycodone, and Fentanyl Before Surgery in Healthy or Mildly Ill Patients

    Not recruiting

    3 1 1
    Norway
  • Study of Trifluridine and Tipiracil in Patients with ER-Positive, HER2-Negative Advanced Breast Cancer After Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    The Netherlands
  • Study on the Effectiveness of Aprepitant and Fosaprepitant in Preventing Nausea and Vomiting in Children Undergoing Chemotherapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study on the Effects of Hyperbaric Oxygen Therapy for Patients with Moderate-to-Severe Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study on Sentinel Lymph Node Mapping Using Gallium-68 Chloride and Tilmanocept in Patients with High-Risk Endometrial Cancer

    Not recruiting

    3 1 1 1
    The Netherlands
  • Study of drug interactions between enzalutamide, morphine and edoxaban in patients with prostate cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study on the Safety and Effectiveness of Apixaban, Edoxaban, and Phenprocoumon for Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Balloon Pulmonary Angioplasty

    Not recruiting

    3 1 1 1
    Investigated diseases:
    The Netherlands

powered by